BLA 761145 · Janssen Biotech
Darzalex Faspro
Daratumumab and Hyaluronidase-Fihj · Injection · CD38-directed Cytolytic Antibody; Endoglycosidase
Accelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 1, 2020
Approved uses
9
Original approval plus efficacy supplements
Registered trials
426
89 Phase 3, 109 recruiting
FAERS reports
3,064
1,414 serious, 121 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 12, 2026.
DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI...
Mechanism: CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including clonal plasma cells in multiple myeloma and light chain (AL) amyloidosis, as well as other cell types. Surface CD38 has multiple functions, including receptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity. Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 27, 2026 Supplement 28 · Efficacy OrphanLetterLabel
- Nov 19, 2025 Supplement 32 · Efficacy OrphanLabelLetter
- Nov 6, 2025 Supplement 29 · Efficacy OrphanLetterLabel
- Jul 30, 2024 Supplement 25 · Efficacy · priority review OrphanLabelLetter
- Nov 30, 2021 Supplement 9 · Efficacy OrphanLabelLetter
- Jul 9, 2021 Supplement 7 · Efficacy LabelLetter
- Jan 15, 2021 Supplement 2 · Efficacy · priority review LabelLetter
- Jan 11, 2021 Supplement 1 · Efficacy LabelLetter
- May 1, 2020 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination Accelerated approvalOrphanLabelLetterReview
1 products under this application
- DARZALEX FASPRO · DARATUMUMAB AND HYALURONIDASE-FIHJ 120MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Daratumumab" as an intervention, any sponsor and status, largest first.
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05552222 · 1,590 participants (planned) · Start Oct 25, 2022 · Primary completion Apr 30, 2031
Drug: Teclistamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Tucson, Arizona; Clovis, California · 270 sites in all
- Pan Tumor Rollover StudyRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03899155 · 1,500 participants (planned) · Start Aug 9, 2019 · Primary completion Aug 25, 2029
Drug: Nivolumab; Ipilimumab and 17 more · For: Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Lynwood, California · 410 sites in all
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04566328 · 1,450 participants (planned) · Start Feb 24, 2021 · Primary completion Dec 31, 2027
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 647 sites in all
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelPivotal-lookingRecruiting
University of LeedsAcademic, hospital or other
NCT07649525 · 1,226 participants (planned) · Start Jul 3, 2026 · Primary completion Jun 2033
Drug: Daratumumab; Lenalidomide and 3 more · For: Multiple Myeloma (MM); Plasma Cell Leukemia (PCL)
Sites: Bristol, United Kingdom; Eastbourne, United Kingdom; Leeds, United Kingdom · 5 sites in all
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT04071457 · 1,100 participants (planned) · Start Aug 13, 2019 · Primary completion Sep 2032
Drug: Lenalidomide; Daratumumab/rHuPH20 · For: Multiple Myeloma
Sites: Anchorage, Alaska; Fairbanks, Alaska; Kingman, Arizona · 842 sites in all
- A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaPivotal-lookingCompleted
Intergroupe Francophone du MyelomeResearch network
NCT02541383 · 1,085 participants · Start Sep 2015 · Primary completion Aug 27, 2020
Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD); Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab and 1 more · For: Multiple Myeloma
Sites: Antwerp, Belgium; Bruges, Belgium; Brussels, Belgium · 107 sites in all
PfizerPfizer (PFE)
NCT05623020 · 1,060 participants (planned) · Start Nov 10, 2022 · Primary completion Oct 18, 2030
Drug: Elranatamab; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Daphne, Alabama; Fairhope, Alabama; Mobile, Alabama · 180 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue225
- product dose omission issue223
- off label use210
- rash163
- diarrhoea141
- nausea118
- dyspnoea105
- neuropathy peripheral104
- neutropenia91
- plasma cell myeloma90
- death86
- dizziness76
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 105 |
| 2021 | 328 |
| 2022 | 511 |
| 2023 | 521 |
| 2024 | 556 |
| 2025 | 570 |
| 2026 | 471 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj)
2024 spending
$103M
Beneficiaries
1,125
7,367 claims
Per beneficiary
$91,304
$629.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,152,437 |
| 2021 | $17,798,801 |
| 2022 | $41,953,678 |
| 2023 | $69,656,584 |
| 2024 | $102,716,642 |
Part B: Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj) · HCPCS J9144
2024 spending
$2.53B
Beneficiaries
26,517
270,709 claims
Per beneficiary
$95,426
2024 ASP limit $50.06 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,046,702,030 |
| 2022 | $1,576,370,371 |
| 2023 | $2,075,948,084 |
| 2024 | $2,530,411,475 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.
Costa LJ, Bahlis NJ, Perrot A, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Usmani SZ, Facon T, Hungria V, et al. · Nat Med 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.